Literature DB >> 24859092

Increased expression of Lgr5 is associated with chemotherapy resistance in human gastric cancer.

Hong-Qing Xi1, Jian-Xin Cui1, Wei-Song Shen1, Xiao-Song Wu1, Shi-Bo Bian1, Ji-Yang Li1, Zhou Song1, Bo Wei1, Lin Chen1.   

Abstract

Leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5), a marker of adult stem cells and cancer stem cells, plays important roles in tumor progression. Furthermore, Lgr5 also contributes to chemoradiotherapy resistance. However, the function of Lgr5 in the prediction of preoperative chemotherapy efficacy has not been reported. We evaluated the potential of Lgr5 in predicting tumor response and overall survival in advanced gastric cancer treated with preoperative chemotherapy. The association between Lgr5 and chemotherapy resistance was also investigated in gastric cancer cell lines. Hematoxylin and eosin staining and immunohistochemical analysis of Lgr5 expression were performed in 68 cases of gastric cancer treated with preoperative chemotherapy. Lgr5 expression was specifically silenced in the AGS gastric cancer cell lines by RNA interference. Levels of Lgr5 mRNA and protein in cell lines were detected by quantitative reverse transcription-polymerase chain reaction or western blotting. Cell viability was evaluated by an MTT assay. Cell apoptosis was assessed by Annexin V-FITC/propidium iodide dual staining analysis. We found that Lgr5 expression was significantly associated with tumor regression grade after preoperative chemotherapy. The rate of positive Lgr5 expression was significantly higher in patients with poor tumor regression compared with those exhibiting tumor regression (P=0.001). Lgr5-positive patients had a significantly shorter survival time than Lgr5-negative patients (P=0.001). Inhibition of Lgr5 expression with small interfering RNA increased the sensitivity of AGS gastric cancer cells to chemotherapy. Our findings suggest that Lgr5 expression may be implicated in the chemoresistance of gastric cancer cells and is a potential novel biomarker for predicting response to chemotherapy and prognosis in gastric cancer patients, and may also represent a potential new therapeutic target for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24859092     DOI: 10.3892/or.2014.3207

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  17 in total

1.  Prognostic significance of leucine-rich-repeat-containing G-protein-coupled receptor 5, an intestinal stem cell marker, in gastric carcinomas.

Authors:  Bo Gun Jang; Byung Lan Lee; Woo Ho Kim
Journal:  Gastric Cancer       Date:  2015-09-19       Impact factor: 7.370

2.  Dipeptide γ-secretase inhibitor treatment enhances the anti-tumor effects of cisplatin against gastric cancer by suppressing cancer stem cell properties.

Authors:  Ryo Kato; Masaya Iwamuro; Hidenori Shiraha; Shigeru Horiguchi; Emi Tanaka; Ken Matsumoto; Atsushi Ohyama; Hiroaki Sawahara; Teruya Nagahara; Daisuke Uchida; Koichiro Tsutsumi; Hiroyuki Okada
Journal:  Oncol Lett       Date:  2018-08-13       Impact factor: 2.967

3.  Clinical significance of putative markers of cancer stem cells in gastric cancer: A retrospective cohort study.

Authors:  Xiao-Long Chen; Xin-Zu Chen; Yi-Gao Wang; Du He; Zheng-Hao Lu; Kai Liu; Wei-Han Zhang; Wei Wang; Chang-Chun Li; Lian Xue; Lin-Yong Zhao; Kun Yang; Jian-Ping Liu; Zong-Guang Zhou; Jian-Kun Hu; Xian-Ming Mo
Journal:  Oncotarget       Date:  2016-09-20

4.  Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer.

Authors:  Hong-Zhi Shi; Yu-Ning Wang; Xiao-Hui Huang; Ke-Cheng Zhang; Hong-Qing Xi; Jian-Xin Cui; Guo-Xiao Liu; Wen-Tao Liang; Bo Wei; Lin Chen
Journal:  World J Gastroenterol       Date:  2017-03-14       Impact factor: 5.742

Review 5.  Wnt Signalling in Gastrointestinal Epithelial Stem Cells.

Authors:  Dustin J Flanagan; Chloe R Austin; Elizabeth Vincan; Toby J Phesse
Journal:  Genes (Basel)       Date:  2018-03-23       Impact factor: 4.096

6.  Regulatory T Cells Promote Overexpression of Lgr5 on Gastric Cancer Cells via TGF-beta1 and Confer Poor Prognosis in Gastric Cancer.

Authors:  Xiao-Sun Liu; Xian-Ke Lin; Ying Mei; Sabir Ahmad; Chong-Xian Yan; Hai-Long Jin; Hang Yu; Chao Chen; Cai-Zhao Lin; Ji-Ren Yu
Journal:  Front Immunol       Date:  2019-07-30       Impact factor: 7.561

7.  Co-Expression of LGR5 and CD133 Cancer Stem Cell Predicts a Poor Prognosis in Patients With Gastric Cancer.

Authors:  Wareeporn Wattanawongdon; Theeraya Simawaranon Bathpho; Taweesak Tongtawee
Journal:  Turk J Gastroenterol       Date:  2021-03       Impact factor: 1.852

8.  LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.

Authors:  Gregory Michelotti; Xiaoyin Jiang; Julie Ann Sosa; Anna Mae Diehl; Brittany Bohinc Henderson
Journal:  Oncotarget       Date:  2015-10-27

Review 9.  LGR5 and LGR6 in stem cell biology and ovarian cancer.

Authors:  Adam J Schindler; Arisa Watanabe; Stephen B Howell
Journal:  Oncotarget       Date:  2017-08-11

Review 10.  Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Authors:  Lia Walcher; Ann-Kathrin Kistenmacher; Huizhen Suo; Reni Kitte; Sarah Dluczek; Alexander Strauß; André-René Blaudszun; Tetyana Yevsa; Stephan Fricke; Uta Kossatz-Boehlert
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.